Research programme: infectious disease vaccines - Themis Bioscience

Drug Profile

Research programme: infectious disease vaccines - Themis Bioscience

Alternative Names: Cytomegalovirus vaccine - Themis Bioscience; Dengue vaccine - Themis Bioscience; Norovirus vaccine - Themis Bioscience; Respiratory syncytial vaccine - Themis Bioscience; Yellow fever vaccine - Themis Bioscience

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Themis Bioscience
  • Developer Institut Pasteur; Themis Bioscience
  • Class Cytomegalovirus vaccines; Dengue vaccines; Respiratory syncytial virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue; Norovirus infections; Respiratory syncytial virus infections
  • Research Cytomegalovirus infections
  • Discontinued Yellow fever

Most Recent Events

  • 13 Dec 2016 Themis Bioscience plans clinical trials for vaccine candidates in early 2017
  • 08 Aug 2016 Discontinued - Preclinical for Yellow fever in Austria (Parenteral)
  • 08 Aug 2016 Early research in Cytomegalovirus infections in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top